Crunchfish receives U.S. Notice of Allowance for patent preventing fraudulent cloning of trusted applications

Crunchfish announced the USPTO issued a Notice of Allowance for its U.S. patent application US 18/843,418 titled “Preventing fraudulent use by cloning of a trusted application.” The patent is intended to prevent fraudulent use via cloning of trusted applications, building on prior grants/decisions in Sweden (SE 546686) and the European Patent Office. This is a positive IP milestone, but no financial figures or guidance changes were provided.

Analysis

This is a moat-extension event, not an earnings event. For a small IP-heavy name, U.S. allowance matters mainly because it improves bargaining power: it can support licensing conversations, deter copycat entrants, and make the asset more relevant in any strategic review. The economic value is highly convex but also highly discounted by the market until there is evidence of monetization.

The second-order effect is on optionality, not near-term revenue. If the company has credible product traction, a stronger patent position can reduce the cost of customer acquisition in fraud-sensitive verticals by making integration claims more defensible; if it does not, the patent simply raises the probability of a sale process or a low-probability enforcement campaign. Competitors in app security or anti-fraud will mostly ignore the news unless they overlap technologically, in which case design-around costs and legal spend rise modestly.

Consensus often overweights the patent grant itself and underweights execution. The key falsifier is absence of follow-through: no licensing, no partnership, no revenue disclosure, and no M&A interest over the next 1-3 quarters. Near term, this can support the shares of the local listing, but the structural move only works if management converts legal IP into cash flow within 6-18 months; otherwise it becomes another paper asset with little market value.

Key Decisions for Investors

• No direct public-market trade on this notice alone; the event is too far from cash realization, so avoid buying generic software/security proxies such as CIBR, PANW, or CRWD on the headline.
• Set a 1-3 month alert on Crunchfish for any licensing, partnership, or litigation-finance update; only reconsider a long if the company can show a monetization path, otherwise this remains dead capital.
• If the shares gap higher on the allowance, treat it as a fade candidate rather than a chase: the upside is limited without revenue proof, while disappointment risk is high once the market digests that allowance is not issuance plus monetization.
• Watch for M&A interest over 6-18 months: small-cap IP holders with granted U.S. claims can become strategic tuck-in targets, but only if the patent maps to a product with demonstrable adoption.